Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, International, Multi Centre Study to Assess the Efficacy and Safety of Intravenous PEG-liposomal Prednisolone Sodium Phosphate (Nanocort) vs Intravenous Methylprednisolone (Solu-Medrol) Treatment in Patients With Acute Exacerbation of Relapsing-remitting Multiple Sclerosis or in Patients With Clinically Isolated Syndrome (CIS).

Trial Profile

A Randomized, International, Multi Centre Study to Assess the Efficacy and Safety of Intravenous PEG-liposomal Prednisolone Sodium Phosphate (Nanocort) vs Intravenous Methylprednisolone (Solu-Medrol) Treatment in Patients With Acute Exacerbation of Relapsing-remitting Multiple Sclerosis or in Patients With Clinically Isolated Syndrome (CIS).

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Prednisolone (Primary) ; Methylprednisolone
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Galapagos NV

Most Recent Events

  • 05 Oct 2016 Status changed from suspended to discontinued.
  • 28 Apr 2012 Additional location (Poland) added as reported by European Clinical Trials Database.
  • 21 Apr 2012 Company (Enceladus Pharmaceuticals) added as trial sponsor/affiliate as reported by European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top